CAR T-Cell Therapy

CAR T-cell therapy is a treatment made from your own immune cells. T cells are collected from your blood, genetically modified in a laboratory to carry a chimeric antigen receptor (CAR) that recognises a marker on the cancer cell, multiplied, and infused back into you as a single dose.

Approved products target CD19 in certain B-cell lymphomas and acute lymphoblastic leukaemia, and BCMA in multiple myeloma, after earlier treatments have failed. It can produce lasting remissions in cancers that had no good options, but it does not work for everyone, relapse is common in some diseases, and it has not yet been proven for solid tumours.

What CAR T-Cell Therapy involves

After eligibility checks, your white cells are collected over 3 to 5 hours by apheresis, a machine similar to a dialysis circuit. The cells are sent to a manufacturing facility, which takes about 3 to 5 weeks; during this time bridging chemotherapy or radiotherapy may keep the disease in check. A few days before infusion you receive 3 days of lymphodepleting chemotherapy, usually fludarabine and cyclophosphamide, to make space for the new cells. The CAR T cells are then given through a drip in under 30 minutes. You are monitored daily, usually as an inpatient, for at least 7 to 14 days for cytokine release syndrome and neurological side effects.

Who is a good candidate for CAR T-Cell Therapy?

Eligibility depends on the exact diagnosis, number of previous treatment lines, organ function and how fast the disease is moving.

• Diffuse large B-cell and some other B-cell lymphomas that are refractory or relapsed after one or two lines of therapy
• B-cell acute lymphoblastic leukaemia in children and young adults that has relapsed or not responded
• Multiple myeloma after several prior lines including the main drug classes
• Mantle cell and follicular lymphoma after specific earlier treatments
• Adequate heart, lung, kidney and performance status, with disease controlled enough to wait for manufacture

It is usually not the right choice if:

• Solid tumours such as breast, lung, bowel or brain cancer, outside a registered clinical trial
• Active uncontrolled infection or active central nervous system disease in many protocols
• Severe heart, lung or kidney impairment
• Disease progressing so quickly that a 4 to 6 week manufacturing wait is unrealistic
• Anyone unable to stay near the treatment centre with a caregiver for at least 4 weeks after infusion

الخيارات التقنية

• CD19-directed products: For B-cell lymphomas and B-cell ALL. The longest follow-up data, with a proportion of patients in remission beyond 5 years.
• BCMA-directed products: For multiple myeloma. High response rates; most patients eventually relapse.
• Commercial versus academic or point-of-care CAR T: Licensed products are made centrally; some university centres manufacture their own under national approval or trials. Ask which you are being offered.
• Allogeneic and CAR-NK cells: Donor-derived, off-the-shelf products are experimental and available only in trials.
• Alternatives: Bispecific antibodies and stem cell transplantation are compared with CAR T for each patient.

ماذا يحدث خلال علاجك

Cell collection and infusion are not painful; both use intravenous lines. The demanding phase is the 2 weeks after infusion, when high fever, low blood pressure, confusion or difficulty speaking can appear and are treated promptly with tocilizumab, steroids and sometimes intensive care. Expect a hospital stay of 2 to 4 weeks in total.

الإعداد لرحلتك

Plan on about 8 to 12 weeks overall: evaluation and cell collection, a 3 to 5 week manufacturing gap (some patients go home in between), then conditioning, infusion and at least 4 weeks staying within an hour or two of the centre with a full-time caregiver.

• Tell the doctor about medication, allergies, pregnancy or breastfeeding, and any history of cold sores, keloid scars or autoimmune disease
• Avoid alcohol, aspirin and anti-inflammatory painkillers for a few days beforehand if your own doctor agrees, to reduce bruising
• Arrive without make-up on the treatment area and avoid sunbeds and strong sun for two weeks before

التعافي والنتائج

Blood counts can remain low for weeks to months, and the normal B cells that make antibodies are often wiped out for a long time, so infections are the main late risk. Many patients need antibody (immunoglobulin) infusions, preventive antivirals and antibiotics, and revaccination. No driving for 8 weeks after infusion. Response is assessed by PET-CT or bone marrow at 1 and 3 months, then at intervals; lifelong monitoring is recommended.

• Back to everyday activity: 2 to 3 months
• When results show: First response scan at about 1 month
• How long they last: Durable in a proportion; varies by disease

سياسة السلامة والمخاطر والتنقيح

Side effects can be life-threatening and are the reason treatment is limited to accredited centres.

• Cytokine release syndrome: fever, low blood pressure and low oxygen, affecting most patients to some degree and severe in a minority
• Neurotoxicity (ICANS): confusion, word-finding difficulty, tremor, seizures, usually reversible
• Prolonged low blood counts and serious infections
• Low antibody levels needing long-term replacement
• A rare inflammatory syndrome resembling HLH
• Relapse, sometimes with cancer cells that have lost the target marker
• A very small risk of secondary T-cell cancers, under regulatory review
• Manufacturing failure, meaning no product can be made

Every written proposal arranged through Clinic-Y states what the clinic covers if a correction is needed. Ask for it before you book, not after.

Cost of CAR T-Cell Therapy in Türkiye

Clinic-Y does not publish a single price for CAR T-Cell Therapy, because the honest figure depends on your case. What moves it:

• The cell product itself, which dominates the total
• Apheresis, bridging therapy and conditioning chemotherapy
• Inpatient days and any intensive care
• Drugs for side effects and immunoglobulin replacement
• Accommodation for you and a caregiver for several weeks

Send your photographs or reports and you receive written, all-inclusive proposals from suitable teams, side by side. Reviewing your case is free.

الأسئلة المتكررة